What's new in the treatment of amyloidosis? Part 2: Cardiomyopathy due to transthyretin amyloidosis
Article Sidebar
Main Article Content
Abstract
Transthyretin deposition amyloidosis is a rare disease caused by the deposition of fibrils of this protein
in various tissues, although the most common manifestations are cardiac and neurological. It can be
acquired (formerly known as “senile amyloidosis”) or hereditary due to mutations in the gene encoding
for transthyretin (TTR).
In 2020, the Amyloidosis Study Group created clinical practice guidelines for treating transthyretin
amyloidotic cardiomyopathy. Since then, published clinical trials have strengthened the available
knowledge, and new lines of research have emerged. This review updates the mentioned guidelines by
exploring the state of the art.
In the case of transthyretin (TTR) amyloidosis cardiomyopathy, therapeutic strategies are predominantly aimed at reducing the production and aggregation of TTR apart from providing supportive treatment for organ damage. Tafamidis, a TTR stabilizer that prevents its aggregation and deposition, is increasingly supported by evidence for its use in improving the survival of patients with this condition. Gene therapies such as messenger RNA silencers or in vivo gene editing to inhibit the expression of the gene encoding for TTR and generate long-term therapeutic effects are under investigation. Multiple monoclonal antibodies have been part of ongoing clinical trials since 2020.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Villanueva E, Carretero M, Aguirre MA, et al. Guía de tratamiento farmacológico específico de la cardiomiopatía amiloidótica por transtiretina, 2021. Medicina (B Aires). 2022;82(2):275-288.
Siddiqi OK, Mints YY, Berk JL, et al. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022;29(2):71-78. https://doi.org/10.1080/13506129.2021.2000388. DOI: https://doi.org/10.1080/13506129.2021.2000388
Tsai FJ, Nelson LT, Kline GM, et al. Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange. Amyloid. 2023;30(2):220-224. https://doi.org/10.1080/13506129.2022.2148094. DOI: https://doi.org/10.1080/13506129.2022.2148094
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368. Errata en: Eur Heart J. 2021;42(48):4901. https://doi.org/10.1093/eurheartj/ehab670. DOI: https://doi.org/10.1093/eurheartj/ehab670
Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493-502. https://doi.org/10.1056/NEJMoa2107454. DOI: https://doi.org/10.1056/NEJMoa2107454
Yadav JD, Othee H, Chan KA, et al. Transthyretin amyloid cardiomyopathy-current and future therapies. Ann Pharmacother. 2021;55(12):1502-1514. https://doi.org/10.1177/10600280211000351. DOI: https://doi.org/10.1177/10600280211000351
Fontana M, Buchholtz K, Engelmann MDM, et al.NNC6019–0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial. Eur Heart J. 2022;43(Supplement_2):ehac544.1767. https://doi.org/10.1093/eurheartj/ehac544.1767. DOI: https://doi.org/10.1093/eurheartj/ehac544.1767